New pill targets Tough-to-Treat lung cancer mutation
NCT ID NCT05393466
Summary
This study is testing a new oral medication called BPI-361175 for adults with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an EGFR mutation, including a hard-to-treat type known as C797S. The main goals are to find a safe and effective dose and to see how well the drug works against the cancer. Participants will take the drug in cycles to see if it can help control their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.